Publications
62
Citations
1,334
Est. group size
~8
Recurring co-author estimate
Active years
18
Publishing since 2008
Diana Zepeda-Orozco's research focuses on kidney injury and disease, particularly the toxic effects that cancer treatments like cisplatin chemotherapy have on the kidneys. Her work spans laboratory studies of the underlying biology (such as oxidative stress and mitochondrial damage in kidney cells), biomarker development to detect kidney damage early, and clinical trials testing protective drugs like avasopasem manganese in cancer patients. She also studies chronic kidney disease more broadly, including in pediatric patients.
Publication output was modest and fairly steady from 2017-2021 (1-4 papers/year) before increasing sharply from 2022 onward, peaking at 19 publications in 2023 and remaining elevated through 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroup
Nature Reviews Nephrology · 2025
- Central Nervous System Iron Content in Pediatric CKD
Kidney International Reports · 2025
- Kidney Function and Injury Biomarkers in Immunocompetent Tumor-Bearing Mice Treated with Cisplatin
Journal of the American Society of Nephrology · 2025
- The antioxidant and anti-inflammatory activities of avasopasem manganese in age-associated, cisplatin-induced renal injury
Redox Biology · 2024
- Redox Regulation of Nrf2 in Cisplatin-Induced Kidney Injury
Antioxidants · 2023
- Mitochondrial Oxidative Metabolism: An Emerging Therapeutic Target to Improve CKD Outcomes
Biomedicines · 2023
- Avasopasem manganese (GC4419) protects against cisplatin-induced chronic kidney disease: An exploratory analysis of renal metrics from a randomized phase 2b clinical trial in head and neck cancer patients
Redox Biology · 2023
- One-year reductions in cisplatin-related chronic kidney disease (CKD) in patients with head and neck (HNC) cancer treated with avasopasem manganese: A prespecified analysis from the phase 3 ROMAN trial.
Journal of Clinical Oncology · 2023
- 1310: GLOMERULAR FILTRATION RATE USING SERUM CREATININE OR CYSTATIN C IN THE PEDIATRIC INTENSIVE CARE UNIT
Critical Care Medicine · 2023
- Urine EGF and TNFR2: A Pilot Study of Novel Biomarkers to Predict Long-Term Renal Outcomes in Pre-Clinical Model of Cisplatin-Induced Chronic Kidney Injury
Journal of the American Society of Nephrology · 2023
- Effects of Avasopasem Manganese on Cisplatin-Induced AKI and CKD
Journal of the American Society of Nephrology · 2023
- Allopurinol Lowers Serum Urate but Does Not Reduce Oxidative Stress in CKD
Antioxidants · 2022
- Mitochondrial Superoxide Dismutase in Cisplatin-Induced Kidney Injury
Antioxidants · 2021
- Uric Acid Lowering and Biomarkers of Kidney Damage in CKD Stage 3: A Post Hoc Analysis of a Randomized Clinical Trial
Kidney Medicine · 2020
- Assessment of Gadobutrol Safety in Combination with Ionizing Radiation Using a Preclinical MRI-Guided Radiotherapy Model
Radiation Research · 2020
- Journal of the American Society of Nephrology×12
- Redox Biology×3
- Antioxidants×3
- bioRxiv (Cold Spring Harbor Laboratory)×3
- Kidney International×2
- Takashi Hato
Medicine · Indiana University
- Danielle Janosevic
Medicine · Indiana University
- Danielle E. Soranno
Medicine · Indiana University
- Pu Duann
Medicine · The Ohio State University
- Cara Slagle
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile